CBCaroline Gertrud Bergner

Caroline Gertrud Bergner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caroline Gertrud Bergner has a total of 209 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatial evolution of microglial phenotypes and iron accumulation in CSF1R ‐associated leukoencephalopathy

    by Julia Lier, Alireza Moein, Alonso Barrantes‐Freer, Dennis‐Dominik Rosmus, Markus Ponleitner, Jonas Franz, Ute Römuß, Evgeniya Kirilina, Annett Halle, Wolfgang Köhler, et al.

    Colony‐stimulating factor 1 receptor (CSF1R)‐associated leukoencephalopathy (CSF1R‐LE) is a fatal genetic white matter disease, whose onset is most commonly in mid‐age adulthood, and is characterized by rapid neurological decline and premature death within a few years after disease onset. CSF1R is exclusively expressed by microglia in the parenchyma of the adult central nervous system, thus defining CSF1R‐LE as a paradigmatic primary microgliopathy. However, the cellular alterations that drive the sudden onset and rapid progression of the disease remain largely unknown. Therefore, the investigation of microglia phenotypes in human histopathological tissue, particularly considering the spatial evolution of the pathology, can provide crucial insights into the disease‐causing mechanisms. In this study, we (immuno‐) histochemically characterized myeloid cell pathology in relation to the extent of damage to the axon‐myelin unit in five autopsy cases of CSF1R‐LE. A particular focus was on the relationship between microglia phenotypes and the pronounced iron accumulation observed in this disease. Our findings provide evidence that the early loss of homeostatic microglia and inflammatory activation of remaining myeloid cells are key components of areas with mild tissue pathology. Furthermore, we demonstrate a marked and progressive accumulation of iron within myeloid cells paralleling increasing white matter damage. This process is associated with ongoing myelin degeneration and occurs in the apparent absence of efficient remyelination. In summary, our study reveals stage‐specific myeloid cell pathology in CSF1R‐LE and highlights a specific spatial heterogeneity that should be considered when studying this disease. Moreover, our findings suggest that cellular iron accumulation may not only contribute to disease progression but may also represent a promising and clinically accessible biomarker for CSF1R‐LE.

  • Analysis of Interindividual Lesion Progression Variability in Adult Cerebral Adrenoleukodystrophy

    by Markus Ponleitner, Julia Lier, Luc Bracoud, Eda G. Kabak, Robert Thompson, Haley G. McLaughlin, Alessandro Delmonte, Thomas Cajgfinger, Lisa Schäfer, Carolin Eva Awißus, et al.

  • Open Access

    Natural History of Clinical Phenotypes and Their Biochemical Correlates in Adult X‐Linked Adrenoleukodystrophy

    by Julia Lier, Markus Ponleitner, Denny Popp, Lisa Schäfer, Franziska Küstermann, Christof Meigen, Frank Kratzer, Joachim Janda, Jürgen Okun, Rami Abou Jamra, et al.

    X‐linked adrenoleukodystrophy (X‐ALD) is a rare monogenic disorder characterized by marked variability in clinical presentation, age at onset, and disease progression. A deeper understanding of its natural history and the relationship between biochemical markers and clinical phenotypes is essential for improving disease monitoring, patient counseling, and optimizing clinical trial design. In particular, the predictive value of very long‐chain fatty acids (VLCFA) for clinical phenotypes has recently garnered increased attention. In this longitudinal, mixed prospective/retrospective, single‐center study, we analyzed clinical and biochemical data from 364 patients with X‐ALD (255 males). Parameters included clinical scores (EDSS, AACS), age at symptom onset, and disease manifestations, which were correlated with individual VLCFA levels. Patients with adrenal insufficiency (AI) exhibited significantly elevated VLCFA concentrations. Higher C26:0 levels were associated with faster progression (measured by EDSS); however, effect sizes were small and inter‐individual variability considerable. Although initial symptom severity was comparable between sexes, males presented earlier and progressed faster. Among patients seen in early clinical stages (EDSS ≤ 4.5), disease progression rates were higher (males: 0.34 ± 0.77; females: 0.11 ± 0.11) than in those presenting at more advanced stages (EDSS > 4.5; males: 0.23 ± 0.33; females: 0.09 ± 0.10). We provide comprehensive data on the prevalence of disease manifestations and the natural course of X‐ALD in a large adult cohort. The observed association between elevated VLCFA levels and adrenal insufficiency should be considered in future clinical monitoring and trial design. However, due to the small effect sizes and variability, VLCFA levels offer limited prognostic utility for individual patients.


  • Open Access

    Use of Brain MRI in Cerebral Adrenoleukodystrophy

    by Hemmo A.F. Yska, Marianne Golse, Damien Galanaud, Hernan M. Amartino, Caroline Bergner, Fabio Bruschi, Florian S. Eichler, Ali Fatemi, ÀNgeles García-Cazorla, Marta Gomez-Chiari, et al.

    Background and ObjectivesCerebral adrenoleukodystrophy (CALD) is a common manifestation of adrenoleukodystrophy (ALD) in men. Early detection of CALD lesions through MRI screening is critical to al...


  • Open Access

    Real-World Outcomes of Risdiplam in 5q Spinal Muscular Atrophy Over 30 Months in Adolescents and Adults: A Multicentre, Prospective, Observational SMArtCARE Study

    by Maggie C. Walter, Markus Weiler, Otgonzul von Velsen, Anika Hüsing, Matthias Baumann, Caroline Gertrud Bergner, Astrid Blaschek, Hakan Cetin, Marcus Deschauer, Astrid Eisenkölbl, et al.

    Background: Risdiplam is approved for the treatment of 5q-SMA from birth for all types and stages. However, broader data for adults are scarce. We aimed to assess safety and efficacy of risdiplam in adults with SMA.Methods: This is an observational cohort study at 38 academic clinical sites in German-speaking countries. Patients with genetically confirmed 5q-SMA (age 16–69 years) were included and received risdiplam treatment for a minimum treatment time of 6 months to a follow-up of up to 30 months. Primary outcome was the change in the total Revised Upper Limb Module (RULM) score, assessed at baseline to months 4-6, 12-14 and 28-30, and based on pre–post comparisons. This study is registered with the German Clinical Trials Register (DRKS00012699).Findings: Risdiplam showed significant motor improvement across a wide phenotypic spectrum of adult SMA patients regardless of age, SMN2 copy number, and functional status. 74% of patients improved or stabilized at 30 months in RULM; patients do not only deteriorate less rapidly but continue to stabilize or even improve at later time points. Maximum RULM improvement was 1.37 points in SMA3 patients at month 12/14, while at all other timepoints, both in SMA1 and SMA2 patients, mean RULM improvement was below 1 and at all time points below the CMC of 2. We did not detect a correlation between RULM improvement and age, sex or body weight, nor significant changes in HFMSE and 6MWT. No new safety findings were detected.Interpretation: Our study provides real-world data from the multinational SMArtCARE registry on efficacy and safety of risdiplam in 194 adult ambulatory and non-ambulatory SMA patients over 4-30 months of treatment.Funding: Financial support for the SMArtCARE registry is provided by Biogen, Novartis and Roche. Declaration of Interest: BS, BK, CB, CS, CR, EH, GSa, GS, MS, OS and VP declare no conflicts of interest. AB received honoraria for advisory board attendance, speaker’s fees from Biogen, Novartis, Roche, Italpharmaco, SantheraMT received honoraria for advisory board attendance, speaker’s fees and research funding from Alexion, Amicus, AstraZeneca, Sanofi Genzyme, Takeda, outside of the present work. AE received speakers´ fees and honoraria for advisory board attendance from Novartis, Biogen, Roche AH received funding for Travel and/or Speaker Honoraria from Roche, Biogen, Novartis, PTC Therapeutics, Santhera, Biomarin, and Takeda. He received research support from Roche, Sanofi, Takeda, Biomarin. AR received speaker fees from Amylyx Pharmaceuticals, ROCHE, Argenx, UCB Pharma, Alexion Pharma, Zambon and ITF Pharma, travel support for congress from Zambon and Johnson&Johnson and served on advisory boards for Biogen and Argenx, outside of the submitted work. ASN reports Adborad Meetings with Roche, Biogen, Novartis and Santhera Pharmaceuticals. CN received honoraria for advisory board attendance, speaker’s fees and travel grants from Biogen USA, Biogen Switzerland, Roche, Sanofi Genezyme, Mitsubishi Tanabe, Alexion, Argenx, Amicus, Johnson & Johnson, Amgen, Jannsen DH received honoraria for advisory board attendance from Novartis. DZ received honoraria for advisory board attendance from Biogen and Amicus, for consultancy from Novartis, and travel support for conference attendance from Zambon, outside of the present work. FK received speaker honoraria from Roche, Amicus, Alexion, Sanofi; travel support for conference attendance from Roche, ITF Pharma and Amicus, and served on advisory boards for Amicus, Roche, and Abcuro. GMzH received compensation for serving on scientific advisory boards (JnJ, Immunovant), speaker honoraria (Amgen, Argenx) and scientific project funding (Biogen). GW has received honoraria for advisory board attendance, speaker’s fees from Roche, Novartis, Alnylam and AstraZeneca outside of the present work. HC received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, and Roche. HK is serving on a scientific advisory board for Novartis and Scholar Rock and received travel expenses and speaker honoraria from Biogen, Pfizer, Roche, and Sanofi-Aventis. HLo received support for research projects and clinical trials from Amplo Biotechnology, AMO Pharma, argenx, Biogen, Desitin, Fulcrum Therapeutics, Harmony Biosciences, KYE Pharmaceuticals, Milo Biotechnology, Novartis, Pfizer, PTC Therapeutics, Hoffman-La Roche Limited, Sanofi-Genzyme, Santhera, Sarepta, Satellos, Spark Therapeutics and Ultragenyx. HL is the Editor-in-chief for the Journal of Neuromuscular Diseases (IOS Press). JJ received compensation for advisory boards and funding for travel or speaker honoraria from Avexis/Novartis, Biogen, IFT, Roche, PTC, Pfizer, Santhera and Sarepta Therapeutics. JKi received honoraria for advisory board attendance, speaker’s fees and research funding from Biogen, Novartis, ScholarRock and Roche. JK received support to attend scientific conferences or meetings from Roche KV received honoraria for lectures, travel expenses, and/or served as a consultant on advisory boards for Novartis, Roche, Biogen, Santhera, Sanofi, ITF, and Scholar Rock. MA received honoraria fro Roche for advisory board attendance. MB received compensation for advisory board attendance and speaker´s honoraria from Novartis, Biogen, Roche and ITF Pharma. MCW has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, PharNext, PTC Therapeutics, Roche, Santhera, Sarepta, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Biogen, Novartis, PTC Therapeutics, Santhera, and worked as an ad-hoc consultant for Affinia, Audentes Therapeutics, Avexis, Biogen, BridgeBio, Edgewise, Fulcrum, Grünenthal, ML Bio, Novartis, Pfizer, PharNEXT, PTC Therapeutics, Roche. MD has received speaker fees, advisory board and consultant honoraria from Biogen, Hoffmann-La Roche, Sanofi and AstraZeneca, outside of the present work....

  • Open Access

    Key lessons from the first international treatment eligibility committee: the case of metachromatic leukodystrophy

    by Daphne H. Schoenmakers, Marije A.B.C. Asbreuk, Tamara Martin, Mareen Datema, Shanice Beerepoot, Michal Inbar-Feigenberg, Samuel Groeschel, Christiane Kehrer, Andreas Øberg, Caroline Sevin, et al.


  • Open Access

    Improving quality of life in rare diseases using disease-specific, multidisciplinary online interventions on the example of rare X-linked adrenoleukodystrophy: a randomized-controlled trial

    by Lisa Schäfer, Astrid Unterlauft, Brit Froebrich-Andreß, Carolin Wollny, Marie Rößler, Ronja Fischer, Carla Bähr, Julia Lier, Daniel T. Wasmus, Christa-Caroline Bergner, et al.

    Background: People with rare diseases (RDs) often require intensive multidisciplinary care in disease-specific centers of excellence (CoE). However, access is limited for most patients living remotely. X-linked adrenoleukodystrophy (X-ALD) is a genetic RD leading to demyelination of the central and peripheral nervous system. Objectives: This randomized-controlled trial tested the feasibility, acceptance, and effectiveness of a multidisciplinary online intervention provided by a CoE on the quality of life (QoL) and well-being of symptomatic women with X-ALD. Design: Single-center, randomized-controlled clinical trial involving 68 German-speaking women with symptomatic X-ALD. Methods: Participants were randomized into an experimental group (EG, n = 34) receiving 12-month online intervention SMART-ALD and a waiting-list control group (WL-CG, n = 34) receiving 6-month SMART-ALD after a 6-month waiting period. Within SMART-ALD, participants were offered regular web-based neurological, social, psychological, and nutritional counseling and fitness training provided by the Leukodystrophy Outpatient Clinic at Leipzig, Germany. Group, time, and interaction effects on primary (self-reported QoL) and secondary (physical and mental health) outcomes after 6-month SMART-ALD were tested by repeated measures ANOVAs. Results: One WL-CG participant dropped out after the waiting period and was excluded from the final analysis. Significant QoL improvements in the EG versus WL-CG were found on self-reported mental health (mean difference (MD): 5.4, 95% confidence interval (CI) (2.8, 13.6), p = 0.020, η 2 = 0.08) and vitality (MD: 8.8, 95% CI (0.1, 17.4), p = 0.002, η 2 = 0.14). Further significant interaction effects emerged for improved knowledge about nutrition (MD: 0.4, 95% CI (−0.7, 1.4), p = 0.002, η 2 = 0.15), socio-medical benefits (MD: 1.8, 95% CI (0.5, 3.0), p = 0.033, η 2 = 0.07), and intense physical activity (MD: 2.2, 95% CI (−3.9, 8.4), p = 0.024, η 2 = 0.10). Conclusion: The study shows that easily accessible, multidisciplinary online interventions provided by the CoE have the potential to improve the QoL in people with RDs by providing regular access to specialized care. Trial registration: This study was registered on ClinicalTrials.gov ( https://clinicaltrials.gov/study/NCT04687007 ).


  • Open Access

    Gene therapy in advanced metachromatic leukodystrophy: tempering expectations

    by Daphne H Schoenmakers, Shanice Beerepoot, Laura A Adang, Marije A B C Asbreuk, Caroline G Bergner, Annette E Bley, Jaap-Jan Boelens, Valeria Calbi, Alejandra Darling, Erik Eklund, et al.

    Recently Zhang et al. ( 2024) published their study entitled “Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: A long-term follow-up pilot study.” The authors present three metachromatic leukodystrophy (MLD) patients treated with gene therapy and claim stabilization or even improvement, despite advanced symptomatic disease stage. The metachromatic leukodystrophy initiative (MLDi) ( Schoenmakers et al., 2022), an international collaborative network and registry for MLD, urges caution in interpreting these results, as the evidence raises several critical concerns. These claims risk fostering false hope among MLD patients and their families, particularly given the significant gaps in the data provided ( Fig. 1).


  • Dominant CST3 variants cause adult onset leukodystrophy without amyloid angiopathy

    by Caroline G Bergner, Marjolein Breur, M Clara Soto-Bernardini, Lisa Schäfer, Julia Lier, Diana Le Duc, Linnaeus Bundalian, Susanna Schubert, David Brenner, Friedmar R Kreuz, et al.

    Leukodystrophies are rare genetic white matter disorders that have been regarded as mainly occurring in childhood. Recent years altered this perception, as a growing number of leukodystrophies was described to have an onset at adult ages. Still, many adult patients presenting with white matter changes remain without a specific molecular diagnosis. We describe a novel adult onset leukodystrophy in 16 patients from eight families carrying one of four different stop-gain or frameshift dominant variants in the CST3 gene. Clinical and radiological features differ markedly from the previously described Icelandic Cerebral Amyloid Angiopathy that was found in patients carrying p.Leu68Asn substitution in CST3. The clinical phenotype consists of recurrent episodes of hemiplegic migraine associated with transient unilateral focal deficits and slowly progressing motor symptoms and cognitive decline in mid–old adult ages. In addition, in some cases acute onset clinical deterioration led to a prolonged episode with reduced consciousness and even early death. Radiologically, pathognomonic changes are found at typical predilection sites involving the deep cerebral white matter sparing a periventricular and directly subcortical rim, the middle blade of corpus callosum, posterior limb of the internal capsule, middle cerebellar peduncles, cerebral peduncles, and specifically the globus pallidus. Histopathologic characterization in two autopsy cases did not reveal angiopathy, but instead micro- to macrocystic degeneration of the white matter. Astrocytes were activated at early stages and later on displayed severe degeneration and loss. In addition, despite loss of myelin, elevated numbers of partly apoptotic oligodendrocytes were observed. A structural comparison of the variants in CST3 suggests that specific truncations of Cystatin C result in an abnormal function, possibly by rendering the protein more prone to aggregation. Future studies are required to confirm the assumed effect on the protein and to determine pathophysiologic downstream events at the cellular level.


  • Open Access

    Case report: Treatment of advanced CSF1-receptor associated leukoencephalopathy with hematopoietic stem cell transplant

    by Caroline G. Bergner, Lisa Schäfer, Vladan Vucinic, Birthe Schetschorke, Julia Lier, Cordula Scherlach, Michael Rullmann, Osama Sabri, Joseph Classen, Uwe Platzbecker, et al.

    CSF1 receptor-related leukoencephalopathy is a rare genetic disorder presenting with severe, adult-onset white matter dementia as one of the leading symptoms. Within the central nervous system, the affected CSF1-receptor is expressed exclusively in microglia cells. Growing evidence implicates that replacing the defective microglia with healthy donor cells through hematopoietic stem cell transplant might halt disease progression. Early initiation of that treatment is crucial to limit persistent disability. However, which patients are suitable for this treatment is not clear, and imaging biomarkers that specifically depict lasting structural damage are lacking. In this study, we report on two patients with CSF1R-related leukoencephalopathy in whom allogenic hematopoietic stem cell transplant at advanced disease stages led to clinical stabilization. We compare their disease course with that of two patients admitted in the same timeframe to our hospital, considered too late for treatment, and place our cases in context with the respective literature. We propose that the rate of clinical progression might be a suitable stratification measure for treatment amenability in patients. Furthermore, for the first time we evaluate [18F] florbetaben, a PET tracer known to bind to intact myelin, as a novel MRI-adjunct tool to image white matter damage in CSF1R-related leukoencephalopathy. In conclusion, our data add evidence for allogenic hematopoietic stem cell transplant as a promising treatment in CSF1R-related leukoencephalopathy patients with slow to moderate disease progression.